Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases

Clinical and Translational Medicine

Table 3 Secondary efficacy endpoints in the current study

	No-Tx Ctrl*	Pre-Tx Ctrl*	Tx	P value
Severity	3.50 (N = 18)	3.05 (N = 115)	5.98 (N = 115)	P < 0.0001 (both controls)
On a scale of 1–7^a	3.50 (N = 18)	3.05 (N = 115)	5.98 (N = 115)	P < 0.0001 (both controls)
Interference with daily life	3.71 (N = 14)	3.20 (N = 59)	6.14 (N = 59)	P < 0.0001 (both controls)
On a scale of 1–7^b	3.71 (N = 14)	3.20 (N = 59)	6.14 (N = 59)	P < 0.0001 (both controls)
Pain	3.74 (N = 19)	3.13 (N = 105)	5.84 (N = 105)	P < 0.0001 (both controls)
On a scale of 1–7^c	3.74 (N = 19)	3.13 (N = 105)	5.84 (N = 105)	P < 0.0001 (both controls)

Tx treatment
* We excluded those participants that had 7 in in the pre-treatment or no-treatment control groups, or did not respond to the question, that is, we excluded those that did not have the specific symptom
^aWhere 1 is “very bad” and 7 is “not bad at all”
^bWhere 1 is “interfered all the time” and 7 is “did not interfere”
^cWhere 1 is “very painful” and 7 is “no pain at all”